This study investigates pancreatic cancer. It focuses on the condition in patients who have resectable or borderline resectable tumors.
The study evaluates the tumor microenvironment using single-cell sequencing technology. It looks at the differences between patients who receive only surgery and those who have preoperative chemotherapy.
- Who can participate: Adults aged 18 to 75 years with resectable or borderline resectable pancreatic cancer can participate. Participants must have no prior anti-tumor treatment and at least one measurable lesion.
- Study details: Participants will be divided into two study arms: those undergoing surgery only and those receiving preoperative chemotherapy. A placebo is not involved in this study.